drug

Mechanism of Disease Progression In AML

ETO2/MTG16/CBFA2T3, a scaffold transcriptional corepressor, drives relapse and determines patient-specific outcome in AML.

Drug Resistance In AML

TBLR1 controls retinoic acid responsiveness in AML.